Headlines about Ardelyx (NASDAQ:ARDX) have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ardelyx earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.1967637879067 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Ardelyx (NASDAQ:ARDX) opened at $6.20 on Wednesday. The stock has a market cap of $297.09, a P/E ratio of -2.78 and a beta of 0.44. Ardelyx has a one year low of $4.05 and a one year high of $15.40.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.10. During the same quarter in the prior year, the firm earned ($0.65) earnings per share. equities analysts anticipate that Ardelyx will post -2.01 EPS for the current fiscal year.

Several research analysts have recently commented on the stock. BidaskClub cut shares of Ardelyx from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Wedbush reaffirmed an “outperform” rating and set a $12.00 target price (down from $13.00) on shares of Ardelyx in a report on Tuesday, November 28th. Zacks Investment Research cut shares of Ardelyx from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $12.00 target price on shares of Ardelyx in a report on Tuesday, November 21st. Finally, Ladenburg Thalmann Financial Services lowered their target price on shares of Ardelyx from $19.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, November 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $12.93.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Ardelyx (ARDX) Share Price” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/02/07/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-ardelyx-ardx-share-price.html.

About Ardelyx

Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.

Insider Buying and Selling by Quarter for Ardelyx (NASDAQ:ARDX)

Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.